{"filing":{"accession_number":"0001193125-26-286273","cik":"0001590750","ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"d164211d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm"},"events":[{"id":14378,"run_id":12798,"accession_number":"0001193125-26-286273","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Viridian announced FDA approval and immediate commercial launch of Lumvoa™ (veligrotug-vvze) for thyroid eye disease treatment, marking the company's transition from development-stage to commercial operations with its first FDA-approved medicine.","company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11777,"accession_number":"0001193125-26-286273","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval and immediate commercial launch of Lumvoa™ (veligrotug-vvze), Viridian's first FDA-approved medicine for thyroid eye disease. This is a material regulatory and operational milestone—the company's transition from development-stage to commercial operations with its lead product. While this could be characterized as a regulatory approval event, it is fundamentally an operational/commercial milestone (product launch) that does not fit the specific event types in the taxonomy; thus operational_other is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:02:46.450422+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11778,"accession_number":"0001193125-26-286273","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Viridian announced FDA approval and immediate commercial launch of Lumvoa (veligrotug-vvze) for thyroid eye disease treatment. This is a material operational and strategic milestone—the company's first FDA-approved medicine and first commercial product—but does not fit the specific categories of earnings_release, exec_departure/appointment, ma_activity, or other named event types. The disclosure centers on a regulatory approval and product launch milestone, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:02:46.450422+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11777,"accession_number":"0001193125-26-286273","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA approval and immediate commercial launch of Lumvoa™ (veligrotug-vvze), Viridian's first FDA-approved medicine for thyroid eye disease. This is a material regulatory and operational milestone—the company's transition from development-stage to commercial operations with its lead product. While this could be characterized as a regulatory approval event, it is fundamentally an operational/commercial milestone (product launch) that does not fit the specific event types in the taxonomy; thus operational_other is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:02:46.450422+00:00","company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","filing_date":"2026-06-26"},{"id":11778,"accession_number":"0001193125-26-286273","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Viridian announced FDA approval and immediate commercial launch of Lumvoa (veligrotug-vvze) for thyroid eye disease treatment. This is a material operational and strategic milestone—the company's first FDA-approved medicine and first commercial product—but does not fit the specific categories of earnings_release, exec_departure/appointment, ma_activity, or other named event types. The disclosure centers on a regulatory approval and product launch milestone, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:02:46.450422+00:00","company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","filing_date":"2026-06-26"}]}